Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
NCL Investment Management, founded in 2015 by Jerry Biggs, is a specialist healthcare venture capital firm based in the United Kingdom. The firm is authorized and regulated by the Financial Conduct Authority (FRN: 838860). NCL focuses on providing transformational equity capital to early-stage, high-growth businesses that are developing innovative technologies aimed at modernizing healthcare.
As of now, NCL manages a portfolio of nine companies, emphasizing sectors such as healthcare technology, biotech, and digital health. The firm has established itself as a key player in the UK healthcare investment landscape, with a notable exit through TC Biopharm, which went public on Nasdaq. NCL's investment strategy is driven by the belief that the modernization of healthcare will be one of the greatest growth drivers of the 21st century.
NCL Investment Management invests primarily in early-stage companies that leverage innovation and technology to address a wide range of health conditions. Their investment strategy encompasses sectors such as healthcare technology, medtech, biotech, digital health, and therapeutics. The firm targets pre-seed, seed, seed-plus, and Series A stages, focusing on high-growth businesses that are pioneering advancements in healthcare.
The firm emphasizes hands-on support for its portfolio companies, assisting them through critical phases such as clinical trials, regulatory approvals, reimbursement strategies, and market access. NCL seeks to partner with entrepreneurs who are at the forefront of transformational change in healthcare, ensuring that their investments are well-positioned for success in a rapidly evolving market.
NCL Investment Management's portfolio includes nine notable companies that are making significant strides in the healthcare sector:
Jerry Biggs - Managing Partner & Founder; previously worked at BOS Investments, HSBC Investment Bank, and Northern Trust Global Investments. He has a background in finance and investment management.
Jonathan Synett - CIO / Managing Partner; brings over 20 years of experience in early-stage and high-growth investments. He holds a degree in Economics & History from Manchester and an MBA from INSEAD.
Pat O’Neill - Managing Partner (US); has over 30 years of senior leadership experience and was previously co-founder, CFO, and COO of KOM Capital, which managed $1.2 billion in assets. He joined NCL in 2019.
Francis Chen - Lead Scientific Advisor; holds a PhD in Immunology from Harvard University and has over 20 years of management experience in the healthcare industry.
To pitch NCL Investment Management, founders should visit their website at nclim.co.uk. It is recommended to include a comprehensive business plan and a clear presentation of the technology or innovation being developed. Founders should expect a response within a reasonable timeframe, although specific timelines are not disclosed. Warm introductions are preferred but not mandatory.
NCL Investment Management has been actively engaging in the healthcare investment space, focusing on companies that drive transformational change. Notably, TC Biopharm, one of their portfolio companies, went public on Nasdaq, marking a significant exit for the firm. This event underscores NCL's commitment to supporting innovative healthcare solutions.
As of now, there have been no recent blog updates or announcements detected on their website, but the firm continues to maintain a strong presence in the healthcare investment community.
What are NCL Investment Management's investment criteria?
NCL Investment Management focuses on early-stage companies in the healthcare sector, particularly those that leverage technology and innovation to address health conditions. They invest in pre-seed, seed, seed-plus, and Series A stages.
How can I apply or pitch to NCL Investment Management?
Founders can submit their pitches through the NCL Investment Management website at nclim.co.uk. It is advisable to include a detailed business plan and information about the technology or innovation being developed.
What makes NCL Investment Management different from other investors?
NCL provides hands-on support to its portfolio companies, assisting them through clinical trials, regulatory approvals, and market access strategies. Their team combines deep industry expertise with a strong scientific background, ensuring that investments are well-positioned for success.
What is NCL's geographic scope?
NCL Investment Management primarily focuses on investments within the United Kingdom, although their expertise and network may extend to opportunities in other regions.
What is the typical check size for investments?
While specific check sizes are not disclosed, NCL typically invests in early-stage companies, which may involve smaller initial investments that can grow as companies progress through their development stages.
What is NCL's post-investment involvement like?
NCL actively engages with its portfolio companies, providing support through various stages of development, including clinical trials and market entry strategies. Their team is involved in guiding companies to ensure they achieve their growth objectives.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.